ArticleJournal of gastrointestinal oncology2026
SOX18 knockdown inhibits colorectal cancer metastasis and angiogenesis through regulation of SAPK/JNK and PI3K/AKT/mTOR signaling pathways.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sex determining region Y-box 18 (SOX18) has been found to be overexpressed in several types of tumors. However, the molecular mechanism underlying the biological function of SOX18 in colorectal cancer (CRC) remains unclear. This study aims to investigate the effect of SOX18 gene knockdown on proliferation, invasion, angiogenesis and its relationship to SAPK/JNK and PI3K/AKT/mTOR signaling pathways in CRC cells. Methods: The Cancer Genome Atlas (TCGA)‑CRC dataset was analyzed to assess the clinical correlation of SOX18 expression. SOX18 was knocked down in OUMS‑23 and HCT116 CRC cells. Cell proliferation, migration, invasion, apoptosis, and angiogenesis were evaluated by functional assays. Western blot and quantitative real‑time polymerase chain reaction (qPCR) were used to detect pathway activity. The JNK agonist anisomycin was applied for rescue experiments, while the AKT inhibitor MK‑2206 was used for pathway validation. Results: High SOX18 expression correlated with poor prognosis in CRC patients. SOX18 knockdown significantly inhibited proliferation, migration, invasion, and angiogenesis, while promoting apoptosis in CRC cells and human umbilical vein endothelial cells (HUVECs). Mechanistically, SOX18 silencing suppressed the phosphorylation of JNK, AKT, and mTOR, and downregulated HIF‑1α/VEGF expression. Anisomycin‑mediated JNK activation selectively restored p‑JNK and fully reversed the tumor‑suppressive and anti‑angiogenic effects of SOX18 knockdown. In contrast, MK‑2206 further inhibited the PI3K/AKT/mTOR pathway without altering JNK activity. Conclusions: SOX18 knockdown suppresses CRC metastasis and angiogenesis by regulating SAPK/JNK and PI3K/AKT/mTOR signaling pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.